Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease

Journal of Psychiatry and Neuroscience

Volumn 34, Issue 2, 2009, Pages 136-142

  Thomann, Philipp A ^a   Kaiser, Elmar ^a   Schönknecht, Peter ^a   Pantel, Johannes ^b   Essig, Marco ^c   Schröder, Johannes ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORYLATED TAU 181; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; LUMBAR PUNCTURE; MALE; MORPHOMETRICS; NERVE DEGENERATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ATROPHY; BRAIN; CEREBROSPINAL FLUID; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PHOSPHORYLATION;

AGED; ALZHEIMER DISEASE; ATROPHY; BRAIN; COGNITION DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 65649123091     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Andreasen N, Minthon L, Clarberg A, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999;53:1488-94.
2. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
3. Schönknecht P, Pantel J, Hartmann T, et al. Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res 2003;120:231-8.
4. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5:228-34.
5. Schönknecht P, Pantel J, Kaiser E, et al. Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia. Neurosci Lett 2007;416:39-42.
6. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
7. Van Hoesen GW, Augustinack JC, Dierking J, et al. The parahippocampal gyrus in Alzheimer's disease. Clinical and preclinical neuroanatomical correlates. Ann N Y Acad Sci 2000;911:254-74.
8. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-39.
9. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 2001;22:747-54.
10. Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002; 58:1188-96.
11. Pantel J, Kratz B, Essig M, et al. Parahippocampal volume deficits in subjects with aging-associated cognitive decline. Am J Psychiatry 2003;160:379-82.
12. Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994;6:63-8.
13. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
14. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001;56:37-42.
15. Schönknecht P, Pantel J, Kruse A, et al. Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. Am J Psychiatry 2005;162:2071-7.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
17. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-65.
18. Aslanidis C, Schmitz G. High-speed apolipoprotein E genotyping and apolipoprotein B3500 mutation detection using real-time fluorescence PCR and melting curves. Clin Chem 1999;45:1094-7.
19. Wahlund LO, Barkhof F, Fazekas F, et al.; European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32:1318.
20. Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999;273:5-8.
21. Good CD, Johnsrude IS, Ashburner J, et al. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14:21-36.
22. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage 2000;11:805-21.
23. Solberg HE; International Federation of Clinical Chemistry. Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. Clin Chim Acta 1987;170:S13-S32.
24. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
25. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-403.
26. Wolf H, Jelic V, Gertz HJ, et al. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003;179:52-76.
27. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-10.
28. Bouwman FH, Schoonenboom SN, van der Flier WM, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007;28:1070-4.
29. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394-401.
30. Kaye JA, Swihart T, Howieson D, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997;48:1297-304.
31. Mega MS, Small GW, Xu ML, et al. Hippocampal atrophy in persons with age-associated memory impairment: volumetry within a common space. Psychosom Med 2002;64:487-92.
32. Bozzali M, Filippi M, Magnani G, et al. The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology 2006;67:453-60.
33. Moossy J, Zubenko GS, Martinez AJ, et al. Bilateral symmetry of morphologic lesions in Alzheimer's disease. Arch Neurol 1988;45:251-4.
34. de Leon MJ, Mosconi L, Blennow K, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 2007;1097:114-45.
35. Hampel H, Burger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005;62:770-3.
36. Fellgiebel A, Siessmeier T, Scheurich A, et al. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 2004; 56:279-83.